Kwality Pharmaceuticals Ltd - 539997 - Board Meeting Outcome for Audited Financial Results For The Quarter And Year Ended 31St March, 2026
Kwality Pharmaceuticals announced record Q4 FY26 revenue of ₹157.11 cr, a 35.8% YoY increase, and FY26 PAT of ₹67.34 cr, up 69% YoY. The company also improved its EBITDA margins to 24% and received an ICRA credit rating upgrade to BBB+.
May 19 2026 11:49:38
Kwality Pharmaceuticals Ltd - 539997 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Kwality Pharmaceuticals has scheduled an analyst/investor conference call on May 19, 2026, at 5:00 PM. The call will discuss Q4 FY26 financial results and will be hosted by Go India Advisors.
May 14 2026 18:16:49
Kwality Pharmaceuticals Ltd - 539997 - Board Meeting Intimation for Considering The Standalone & Consolidated Audited Financial Results For The Quarter And Year Ended March 31, 2026
Kwality Pharma will hold a board meeting on May 19, 2026, to consider and approve the standalone and consolidated audited financial results for the fourth quarter and financial year ended March 31, 2026. This meeting will decide the company's financial performance for the last quarter and the full fiscal year.
May 08 2026 16:37:49
Kwality Pharmaceuticals Ltd - 539997 - Announcement under Regulation 30 (LODR)-Credit Rating
Kwality Pharmaceuticals Ltd's credit rating has been upgraded by ICRA to [ICRA]BBB+ (Stable)/[ICRA]A2. The company was also removed from the 'Issuer Not Cooperating' category, reflecting improved financial health and compliance.
May 08 2026 10:39:08
Read More